

## **Supplemental Material to:**

**C Buddy Creech, Cornelia L Dekker, Dora Ho, Shanda Phillips, Sally Mackey, Cristina Murray-Krezan, Maria Grazia Pau, Jenny Hendriks, Valerie Brown, Leonard G Dally, Isabella Versteegen, Kathryn M Edwards**

**Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults**

**2013; 9(12)**

**<http://dx.doi.org/10.4161/hv.26038>**

**[www.landesbioscience.com/journals/vaccines/article/26038](http://www.landesbioscience.com/journals/vaccines/article/26038)**

**Supplemental Table 1: Increase in AST and ALT in subjects within 14 days after vaccination**

Dosage Received	Subject	Days Post-Vaccination [Vaccine Number]	ALT (U/L)	AST (U/L)
10 <sup>8</sup> vp/mL	A	9 days [1]	27	48
10 <sup>9</sup> vp/mL	B	7 days [3]	64	33
	C	9 days [1]	64	25
		8 days [3]	64	30
	D	7 days [2]	84	48
		14 days [2]	61	27
10 <sup>10</sup> vp/mL	E	7 days [3]	40	48
10 <sup>11</sup> vp/mL	F	8 days [2]	63	24
	G	8 days [2]	32	43
	H	9 days [1]	30	43
Placebo	I	7 days [2]	51	45
	J	9 days [3]	66	28
	K	7 days [2]	80	120
		14 days [2]	75	33
		7 days [3]	62	32
		14 days [3]	83	45
	L	7 days [1]	43	31

*P > 0.10 for difference in frequency of subjects with increased ALT or AST between vaccine groups and placebo.*